Tzar has a proprietary technology of isolating progenitor stem cells from the blood and using genetic expression of these cells and algorithms to detect HrC and distinguish between cancer absent, cancer imminent and cancer present and also distinguish between different stages of cancer. It also uses exome and transcriptome analysis to provide primary organ, primary disease, pathways impacted and secondary tumour analysis. The data is not only useful in terms of early detection but also helps oncologists decide appropriate treatment protocols, analyse treatment efficacy and improve response time and efficiency. This technology will save lives by improving detection and analysis with a simple blood test.